Meeting
2015 Gastrointestinal Cancers Symposium
Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).
Authors
Ann-Lii Cheng
National Taiwan University Hospital, Taipei, Taiwan
Ann-Lii Cheng , Gerardo H. Cornelio , Lin Shen , Timothy Jay Price , Tsai-Sheng Yang , Ik-Joo Chung , Guanghai Dai , Jen-Kou Lin , Atul Sharma , Kun-Huei Yeh , Brigette Ma , Adel Zaatar , Zhongzhen Guan , Nehal Masood , Vichien Srimuninnimit , Thomas Cheung Yau , Frank Beier , Sudipto Chatterjee , Robert S.C. Lim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Clinical Trial Registration Number
NCT00778830
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 566)
DOI
10.1200/jco.2015.33.3_suppl.566
Abstract #
566
Poster Bd #
B10
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild‑type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC).
First Author: Lee Steven Schwartzberg
Poster
2018 ASCO Annual Meeting
Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.
First Author: Timothy Jay Price
Poster
2018 Gastrointestinal Cancers Symposium
Impact of primary tumor side (TS) on outcomes of once-every-2-weeks (q2w) cetuximab + first-line (1L) FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.
First Author: Timothy Jay Price
Poster
2016 ASCO Annual Meeting
A randomized multicenter phase II study of FOLFIRI plus either panitumumab (Pmab) or bevacizumab (Bmab) as second-line treatment for wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) with exploratory biomarker analysis by liquid biopsy: WJOG6210G.
First Author: Kohei Shitara